ArticlePloS one2025
Prognostic factors associated with recurrence in patients undergoing surgery for hepatic cystic echinococcosis: A systematic review protocol.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Postoperative Prophylaxis of Cystic Echinococcosis with Albendazole and Praziquantel: A Retrospective Cohort Study.Biomedicines · 2026Article
- Risk factors for recurrence following surgical treatment of pediatric hepatic hydatid disease.Pediatric surgery international · 2026Observational
- Impact of recurrence of hepatic cystic echinococcosis on postoperative outcomes in an endemic region of Chile: a retrospective cohort study.Tropical medicine and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic echinococcosis (CE) is a zoonotic disease caused by Echinococcus granulosus, with hepatic localization being the most frequent presentation in humans (70-80%). Surgical intervention remains the most common therapeutic option, despite an associated recurrence rate of 8% (95% CI: 6%-10%). CE recurrence increases postoperative morbidity, hospital stay, and healthcare costs. Several prognostic factors (PFs), such as cyst size, presence of multiple cysts, and personal or family history of CE, have been linked to recurrence. However, associations with cyst location, type, and biliary complications remain uncertain due to conflicting evidence. This systematic review (SR) aims to identify PFs associated with recurrence in patients undergoing surgery for hepatic CE.
methodsWe will conduct a systematic review of primary longitudinal observational, and experimental studies evaluating the association between clinical, parasitic, and surgical PFs and CE recurrence. We will search Medline, Scopus, Embase, Web of Science, BIREME-BVS, and SciELO using a sensitive search strategy. Two reviewers will independently screen studies, extract data, and assess risk of bias using the QUIPS tool. Methodological quality will be assessed using MInCir-Pr2, and data extraction will follow the CHARMS-PF checklist. A qualitative synthesis will be performed, and where appropriate, random-effects meta-analyses will be conducted using the inverse-variance and restricted maximum likelihood methods. Heterogeneity will be assessed using Chi², Tau², I², and 95% prediction intervals. Publication bias will be explored via funnel plots and statistical tests (Egger's). Certainty of evidence will be assessed using GRADE. DISCUSSION: The results of this SR will support early risk stratification and inform clinical decision-making in the management of hepatic CE, a neglected tropical disease. REGISTRATION: PROSPERO, CRD42024538005.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.